Leonard P. Wessell III
President
Amerop Holdings, Inc.
1800 Broadway, Suite 100
Boulder, CO 80302
(303) 938-0507
|
CUSIP No. 627335201
|
|
|
1
|
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Amerop Holdings, Inc. – IRS Identification No. 84-1160226
|
||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
|
||
3
|
SEC USE ONLY
|
||
4
|
SOURCE OF FUNDS*
WC
|
||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
[ ]
|
||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Colorado
|
||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
2,211,781
|
|
8
|
SHARED VOTING POWER
0
|
||
9
|
SOLE DISPOSITIVE POWER
2,211,781
|
||
10
|
SHARED DISPOSITIVE POWER
0
|
||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,211,781
|
||
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
[ ]
|
||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
15.3%
|
||
14
|
TYPE OF REPORTING PERSON*
CO
|
CUSIP No. 627335201
|
|
|
1
|
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Leonard P. Wessell III
|
||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
|
||
3
|
SEC USE ONLY
|
||
4
|
SOURCE OF FUNDS*
PF
|
||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
[ ]
|
||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
2,211,781
|
|
8
|
SHARED VOTING POWER
0
|
||
9
|
SOLE DISPOSITIVE POWER
2,211,781
|
||
10
|
SHARED DISPOSITIVE POWER
0
|
||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,211,781
|
||
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
[ ]
|
||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
15.3%
|
||
14
|
TYPE OF REPORTING PERSON*
IN
|
· |
All of the proceeds of the proposed transaction will be used solely to repurchase and retire immediately at the closing of such proposed transaction the Notes, together with accrued interest, and all rights related thereto.
|
· |
Amerop will have the option to purchase from the Company up to an aggregate of 7 million additional shares of Issuer Common Stock at any time over the period of 18 months following the closing, at Amerop’s sole option, at a price equal to the 60-day volume weighted average on the business day prior to such option being exercised by Amerop. Such option may be exercised up to 7 times (in no less than 1 million share increments) during such applicable 18-month period.
|
· |
Amerop will have representation on the Board of the Issuer commensurate with its ownership of Issuer Common Stock after the closing of the proposed transaction; and
|
· |
Amerop shall have certain customary registration rights, including “piggy-back,” demand registration and holdback rights.
|
Item 6.
|
Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
|
Not applicable.
|
|
Item 7.
|
Materials to be Filed as Exhibits
|
A
|
Amerop Proposal, dated October 17, 2017
|
B
|
Letter, dated September 11, 2017
|
AMEROP HOLDINGS, INC.
|
|||
By:
|
/s/ Leonard P. Wessell III
|
||
Name:
|
Leonard P. Wessell III
|
||
Title:
|
President
|
By:
|
/s/ Leonard P. Wessell III
|
||
Name:
|
Leonard P. Wessell III
|
Name
|
Present Principal Occupation or Employment /
Name and Address of Employer or other Organization
|
Address
|
Citizenship
|
|||
Leonard P. Wessell III
|
Sole Director and President, Amerop Holdings, Inc.
|
Amerop Holdings, Inc.
1800 Broadway, Suite 100
Boulder, CO 80302
|
United States
|
· |
Amerop will purchase $18 million of newly issued shares of common stock, par value $0.001 per share, of the Company (the “Company Common Stock”) from the Company at a price of $1.96 per share, resulting in Amerop purchasing 9,183,675 shares of Company Common Stock. Amerop does not require a financing condition or contingency.
|
· |
All of the proceeds of such purchase of Company Common Stock will be used to repurchase and retire immediately at closing the Notes and all rights related thereto.
|
· |
Amerop will have the option to purchase from the Company up to an aggregate of 7 million additional shares of Company Common Stock at any time over the period of 18 months following the closing, at Amerop’s sole option, at a price equal to the 60-day volume weighted average on the business day prior to such option being exercised by Amerop. Such option may be exercised up to 7 times (in no less than 1 million share increments) during such applicable 18-month period. The proceeds resulting from Amerop exercising such option will further strengthen the Company’s balance sheet and will allow the Company to execute its growth initiatives.
|
· |
Follow the governance guidelines set forth in the Form of Corporate Governance Guidelines of the Company, adopted by the Board on May 8, 2015.
|
· |
Enter into an executive recruitment search for senior management with relevant industry experience who are capable of driving value for all stockholders of the Company.
|
· |
Establish a stable, long-term capital structure that will be conducive to increasing Company stockholder value and providing a path to long-term solvency.
|
· |
Provide transparency and future guidance to the market to bolster Company stockholder confidence and to provide accountability.
|
Issuer
|
MusclePharm Corporation
|
Price and Amount
|
The Investor will purchase $18 million of newly issued shares of common stock, par value $0.001 per share, of the Company (the “Company Common Stock”) from the Company at a price of $1.96 per share, resulting in the Investor purchasing 9,183,675 million shares of Company Common Stock. If there is accrued interest on the Notes (as defined below), the amount of Company Common Stock that the Investor will purchase will be increased in an amount equal to such accrued interest at closing.
|
Use of Proceeds
|
The proceeds from the Transaction will be used by the Company solely to repurchase and retire immediately at closing the following three secured promissory notes of which Ryan Drexler, the Executive Chairman of the board of directors (the “Board”) of the Company and the Chief Executive Officer of Company, is the holder: (i) the Convertible Secured Promissory Note, dated December 7, 2015, as amended by the First Amendment to such Convertible Secured Promissory Note, dated January 14, 2017, in the original principal amount of $6,000,000, (ii) the Convertible Secured Promissory Note, dated November 8, 2016, in the original principal amount of $11,000,000, and (iii) the Secured Demand Promissory Note, dated July 27, 2017, in the original principal amount of $1,000,000 (together, the “Notes”).
|
Source of Funds
|
The Investor intends to fund the Transaction using funds available to it and to entities wholly owned and controlled by Leonard P. Wessell III. There will be no financing condition or contingency with respect to the Transaction.
|
Working Capital Option
|
The Investor will have the option to purchase from the Company up to an aggregate of 7 million additional shares of Company Common Stock at any time over the period of 18 months following the closing, at the Investor’s sole option, at a price equal to the 60-day volume weighted average on the business day prior to such option being exercised by the Investor. Such option may be exercised up to 7 times (in no less than 1 million share increments) during such applicable 18-month period.
|
Representations and Warranties
|
Customary representations and warranties from the Company and the Investor for a transaction of this type.
|
Publicity
|
The Investor will have the right to consent to any use of its name (or the name of any of its affiliates) in any press releases or public statements issued, or any governmental or regulatory filings made, by the Company.
|
Target Closing
|
On or prior to November 3, 2017.
|
Fees and Expenses
|
Each party will be responsible for its own fees and expenses related to the Transaction.
|
INVESTOR RIGHTS
|
|
Board Representation
|
The Investor will have Board and committee representation commensurate with its post-Transaction ownership percentage.
|
Protective Provisions
|
Customary governance rights and covenants for a transaction of this type.
|
Preemptive Rights
|
In the event that the Company determines to issue any shares of Company Common Stock or any securities convertible, exchangeable, exercisable, or redeemable, in each case, into Company Common Stock other than pursuant to the Company’s option plan or other standard exceptions, the Investor will be entitled to purchase, on a pro rata basis, additional shares of Company Common Stock or securities convertible, exchangeable, exercisable, or redeemable, in each case, into Company Common Stock in such amounts as is necessary to maintain its fully diluted percentage of equity ownership at the same level as it existed prior to such issuance by the Company.
|
REGISTRATION RIGHTS
|
|
Demand Registration
|
The Investor will have the right on two separate occasions to require the Company to file a registration statement under the Securities Act of 1933 for the public sale of such number of shares of Company Common Stock as the Investor may request provided that the aggregate offering price of such shares is at least $3,000,000. The Company will use its best efforts to cause such shares to be registered subject to customary underwriter cutbacks, pro rata based on total holdings. If a registration statement is withdrawn as a result of changes in conditions at the Company, it will not count towards such demand rights.
|
S-3 Registration
|
Holders of registrable securities will be entitled to two Form S-3 registrations per year, if available for use by the Company, and unlimited shelf takedowns under such shelf registration statement subject to no more than two fully marketed offerings in any one-year period.
|
Piggyback
|
The Investor will be entitled to unlimited “piggyback” registration rights on registrations initiated by the Company or any other stockholders of the Company, subject to customary underwriter cutbacks.
|
Priority of Demand
|
The shares of Company Common Stock of the Investor will have priority in all registrations over all other shares except for registrations initiated by the Company in which case the shares of Company Common Stock being sold by the Company for its own account will have priority.
|
Registration Expenses
|
The Company will pay the customary cost of registration, including registration and filing fees, exchange listing fees, printing expenses, fees and expenses of counsel for the Company, and the reasonable expenses of one counsel for the Investor and state blue sky fees. The Investor will pay underwriting discounts and selling commissions.
|
Holdback / Lockup
|
The Company will be subject to a customary holdback of up to 180 days and will agree to sign any reasonable lockup requested by the underwriter in connection with an offering.
|
DOCUMENTATION
|
||
Note Purchase
Transaction Documents
|
||
i.
|
Stock Purchase Agreement
|
|
ii.
|
Stockholders’ Agreement (containing registration rights)
|
|
iii.
|
Amended and Restated Certificate of Incorporation (to the extent necessary)
|
|
iv.
|
Various and other documents and amendments (to the extent necessary)
|
|
· |
Note 1: Initial principal amount of $6,000,000 with interest accruing at an initial rate of 8% per annum, dated December 7, 2015. This note was rolled over on January 15, 2017, with its interest rate increasing to 10% as a result. This note was initially convertible for 2,608,696 shares of common stock, at a price of $2.30 per share. Any unpaid interest was also convertible to common stock at a price of $2.30 per share. It is unknown what impact the rollback had on conversion terms. This note is secured by a lien against all the assets of MusclePharm, and allows the holder to appoint two directors to MusclePharm's board.
|
· |
Note 2: Principal amount of $11,000,000 with interest accruing at a rate of 10% per annum, or 12% in the event of a default, dated November 8, 2016. The note comes due in November 2017. This note is convertible for 6,010,929 shares of common stock at a price of $1.83 per share. Unpaid interest is convertible at the same share price. As with the first note, the second note grants the note holder security in virtually all of MusclePharm's assets. Furthermore, it appears this note improperly grants its holder voting power in MusclePharm equivalent to 10,156,020 shares.
|
· |
Note 3: There is not that much information publicly disclosed about the third note, other than the principal amount is $1,000,000 with interest accruing at a rate of 15% per annum. This note was recently issued on July 27, 2017. It is unknown whether the third note is convertible to shares of common stock. As with the other two notes, the third note is secured by a lien on all MusclePharm's assets.
|
cc: |
Amerop Holdings, Inc.
|
MJXN8''&-W./I7VI7S-^U-I<4>LZ-J&W#3JT;$#KMH ]Q^'7BR/QIX'L=70CS M'79*!V=>#745\\_LL:P\EGK&CNQVP%9D4GIN->Y>)=770/#-_JCXQ:PF3FGU M ^8OVB/B)-K7B4^'+"8#3[$YV MU_1+K3+Y0T-S&4;(Z>]7Z* /A_2-9O\ X6_%)S&Q5;6Z*2(>!)'GO^%?;&GW ML>HZ;;WD!#1SQK(I!]1FOC[]HG3%L?BY M9_O+_.@#Z&IDT,=Q \,Z!XW&UE89!%/HH ^._B_XV@D(G@9>-K]P*^F/AKXP3QOX*M=5^43']W*H/1AP:\Z_:ATM;GP M7I]^%7?:W)!/?!'2N>_97UIVN]9TAW.P(LT:=@ V:^\-W A@?25,EB2>%XI5#HX*LI'!%/H MI >#_"?PW_PBOQV\5:>@Q$UN)(QZ*S9KWBL.'PK9P^-;CQ*CN+JXMEMW3C:0 MO0UN4 %%%% !1110 4444 %%%% !7FOQ# _MV'WB%>E5YG\1./$,'H8P*\S- M/]V94-SL/!XQX8MOQ_G6Y6+X2&/#5M^/\ZVJ[,/_ 8^B$]SQ2__ .0Q=_\ M75NGUJ!\JU27I8ZU=_\ 75OYU&Q/?BOB*O\ $9T+8C)X&.#3^J\\'MBHU'SC M/ J7HH[>U9@"#@;C]*D1_04W@[0OK3E^0 ].>U(HDMY6@NHYA\K(P8$5[):3 M+<6<4J'<'0'(KQ=QSG->C>!-1^UZ.UNYS) W3V/2O +:C9M8:M<6A&2)2%P/4U[77(:SX<%SXTLKS86BDYD&.!BO3S+ M#NM"+CNG^9G!V9O:#8+INBV\ Z[=S?4\UYOXLU,ZKX@8(W[J$[4YX!'6O2-> MO?[-T.XG7 94PHKQZ,[G:1^K-DXKDS*:I4HT(CAJ[CSQQT!ZXJ_HM^=.UJUN M2?D5\/\ 0U2( QVIC*#C/ ]J\&$G&2DNAL]CV]6#HK+R&&12UD>%K[[?X?MY M"?F0;&_"M>ON: :VEU*TCN6M6+1>8N0I(P35^O-OC M-X[UCP3H-E_PCUJL]W?2M$"5+% !G( K01U.JQ>%=$M6N-5BTZUC09/F*HS] M!7C.O?%2VUN^;2?AQX4CNY2=GVN2U^5?<8K.TGPC;^))DU;XF>(KZ\F;YOLB MJ2@'I7KFAZWX*\.6:P:-;BUC48REN03^-&M] TZG :#^S]-K=ZNL>/[]I9W M(M8#\H'H>*]NTK2K/1-,AT_3(%@MH5VHB]!6'+\0] BA:1YIL*"3B$]JV-#U M>'7=&@U&V#"*<;E##!QFBP7N:%>5?M#Z$FJ_"^XN]FZ33V\U3CH.AKU6L;Q? MIHUCP=JFGE=WGVS+C'7C- 'S+^S7X@_LSQ]-ISGY-1A"*">A&37UG7PA\/M2 M/AWXIZ7/*2JV]YL<=P,D&ONI[F-+,W+'$83S,^V,T >0I8?\)A\>M=,N'M=+ MT](8O0.P(->'_#2^E\+?':W@\QHXVO7@E!X##)KW[X&P/>:;K?B&?)DU'490 M">NU6(%?/_Q?L9?"WQINI8/W?[Q+F,CCKS0QGVKG/2O'?C&/^$@\;>#O"\1) M\R\,\Z@<;0/_ *U>IZ%>+J'A^PNT8,)K='R#ZJ*\PT>+_A)/VD-7OB=UOHUG M''%W <\&@1Z9K,G]G^&;QXR1Y%LVTCV6O@)V^T:Q*\G/FW)R?7+5]\>+!GPC MJ@'_ #[/_*O@N QB^P^"?M''M\U/H,^_=#C$7A_3T P%MHQ_XZ*O53T@[M$L M3ZV\?_H(JY2$%>!_M4Q*?#>B2X^<7+JI_ 5[Y7@G[5 9$$/XD5X;^S*AG^)%W+_ 'XVQL^U _I7W5TKX:^$1C3XJ M>'MQ/-SP/PK[EJ0"BBB@#Y5_:AA$7C?3[A?O/ ?PKHOV5;J1[?7+9B=B%' M],UA_M28;Q=I2CKY/-;/[*R_/K[C./W8Y_&D-FE^U'@^'=(!)YF;C\*I_LK@ M?V?K)''S+_.KG[4F!X ,_"]KXQ\*WFC7@&)TPC]T;L:^+?$7A/Q%\-O$:K<^; M:R1RY@NHB<>Q!]:^[ZR/$GA;2?%FE26&MVD=Q$P(!9 '1_&TF9&.V.^QU_W_\ &OH*WN(;N!9K:5)8F&5=&R#7R#\4_@KJ7@B1M0TO M=>Z0>I R\?U '2LWX=?&C7? ]QY,CF^TYB-UO,Q.S_=]#1>XK-'VI16#X1\8 M:5XTT6/4='G#J1\\9^\A]"*WJ "BBB@ HHHH **** "BBB@ KS/XB?\ (>@Q MVC&:],KS/X@_\C%%CO$*\S-/]V?JBH;G9>$L_P#",VN?0_SK:K'\*C'ANU^A MK8KMH?PH^B$]SQ>:54UF\+1+)F5L;CTYJO>.)IMT<8C4C[H-27+ ZS=G'_+5 MN/QJ%AE@3WKXFJ_>:\S=#%QD M*?FZD^E9#%5 GJ*EM;@V5W#< MKUC<,*Z,/4=*I&:Z$M71[7145K.MS:13)R)$##\13Y9%AB:20X50237W2::N M E<:JC:!Z'\ZGO[QM3U>XNWY+.<9]!TJ#[Q':OB M\76]M6 WPWW%F3@8#J/YU MW5>1^')WM?$-D\?1WVD#N*] &K>V@D&4FN'/-4=1\#_$S4O(?Q-XODM( M)YE0PVLIXW4 YZ?XC\5^#O#5J\FK7%D"JG]TNUF/MBM3PE>V^H^%K*[ MLH5@MY4W1QKT"D\5Y]I?[/'ABWD$VLW%UJ\Q^^;ELAOPKU*PL+;3-/ALK&)8 MK>! D:+T4"DDD3=O M%%,#X4^(>F-X<^)FIQ*@0Q7/G+@XR"*_$ M8M_@3 '_ +3&C?8_B!;ZFBX2[@53[D"M73]=?Q!\*?!W MAM)?,DO]0:WF!/\ O.*749[A\,=&.A?#O2K1OOM$)7X[MR?YUX5^U-HGE^( M--U88 N(_*)]UKZ P7I5'X&6KW5GKOB*?/F:CJ$JC)_A5B!7E?PA\ M9'1OA7XMLW Z M3=6S=)8F7\Q7Y]W]N]MJE\@X,$[_ %X8U^AW6OB/XP>&)/"_Q(U"W("P71\] M&'<-SBGT&C[%\)W:WW@_2KA#D/:1\^^T5KUYG\!->CUKX6V<>_=-9LT+J3R, M'BO3*0@KYS_:LO4\K0K0$%@SR$5]&5\=_M#:ZFN?$R:WAE+06$*H!G(W=Z . MF_95L?-\1:Y?,NT1P(@],DFO9OC+8-J/PCUV&-=SBWW*/H17._L[^%6T#X=K M>746RZU"0R'CG9_#7J5_91:CI\]G<*&BG0HP/<&F!\'> +O^S_B!H5P_ ANE M)S7WO$XDA1QT9017P+XDTV?POXMO].F0I+;7#-'GCC.1^E?;W@C68M>\%:7? MP,&$EN@;!Z,!@T@-ZBBD9@B%G("J,DGM0!\D?M(WYN?BF+5/^7>WCSGMD5Z1 M^S!IC0>";W4'&/M-RR#WVUX1\1=6?Q9\3-2N; 7_>(R:+ >4_M3M_Q(='0C.Z5_Y5%^RN/^)1K'_71>:D_:EYT? M10/^>KGI[4S]E@?\2?6#G_EH*8'T#1112 \@_:3OEMOAHMNQ(-S.%&!Z .Y-:?[3_B>.ZUG3?#T)R;3,TN#U+#@5VO[.'A&30_ M!DVJWRT5P?Q,UJXT2\\,3PW#PQ2:HJ3!3@.I'0^U=V" M&4$<@C(H 9<6T-W;O!=1++%(,.CC(85\V?&[X*V6BZ7+XF\+1"*&$[KJV X4 M?WA^-?2]8_BZUBO?!^JV\ZJT 9:Y\3-<@^(5UX6\ M.Z!#J$UM$LK/),4X(K8\)^/9]8\07/A[7=+;3-7MXA,8PVY&0],'UI%6:5SM M:*\[U#XEWE_X@N=%\#:2-6NK'_C[DF8I&GL".IK4\(^.FU[5;K1=5L'T_5[1 M!)+%U0J>ZGO0+S.PHHHH **** "O-/B"?^*BB[?NA7I=8NK>%K'6;Q;F[W[U M7;\IKBQU&=>CR0W*B[,?X7_Y%RU_W:UZ@LK2*PM$MX 0B# S4]=-*+C!1?0D M\2O!_P 3BYP/^6K( PY]*>J_+TKTD>!=+&/FEZ^M'_"#:9_>E_.E_96(\OO'S MH\U"$MT'M4FTX''>O1E\"Z6I!!EX]Z=_PA&F_P!Z7KZBI_LG$^7WC]HCS1E( M_/I2,I=<8_ ]*],_X0C3-N,R=<]13?\ A!=+_O2_G1_9.)\OO#G0WP-J7VK1 M_LLC9EMS@_3M4GC;4_[/T%XUQON/D'/;O5[1_#UKHLDCVC.3(,$,:36?#MIK MDD37C2?NONA3Q7NQIUUA/9_:M8RTN>30QE4& 1DT!2"1C!^M>E_\(1IH& TH M_&F?\()IF<[YOS%>)_96(\OO-.='G(&%7O0V1@=LUZ/_ ,(+IF -TO!SUI1X M&TP)MWR]<]13_LO$>7WASHX71,'7K$ X'FBO7ZYVT\%:;9W44\1DWQMN7)[U MT5>OE^&J8>,E/J9R=PJK?Z99:K;_ &?4K6*ZB_N2J&%6J*],DYF;P/9QX.BW M=UI!!R!:/A?^^3Q67K&B^,DM(8[&\L]4$$RRK]JRCMCMD5W5% ''W7CTZ/;[ MM?T34+8J/G>&+S8\_4=JZ#0M537-$MM1B7:EPNY0?2KLT,=Q"\,RAXW4JRD< M$5%86,.FV,5I:KMBB&%'H*8%BBBBD!XG^TQX<74/!EMK"CYM.D)?'=3Q7FO[ M.VBG7O'R7,DC&WT=//C0GY0[9'2OJK5=)L=;TV6PU6VCNK688>*095JHZ!X. M\/\ A9I6\/Z3;6#2C$AA3!8>] &U6+XPTG^W?!NJ::.#<6[*#[]:VJ" 001D M'K0!\'^#K*YO/'%IH$$K#[3=B&6,'AP#W_*ONRWB$%M%$O C0*/P&*YW3_AS MX2TK6!JEAH5I#>JYD$ZI\P8]3734 %>;?q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end